Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2026-03-03 @ 12:34 AM
Study NCT ID:
NCT03021460
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-19
First Post:
2017-01-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Melanoma | View |
| None | Stage III Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIA Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIB Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIC Cutaneous Melanoma AJCC v7 | View |
| None | Stage IV Cutaneous Melanoma AJCC v6 and v7 | View |
| None | Unresectable Melanoma | View |
Keywords: